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Introduction: Ventilator-associated respiratory infection (VARI) is an important cause of morbidity in critically-ill
patients. Clinical trials performed in heterogeneous populations have suggested there are limited benefits from
invasive diagnostic testing to identify patients at risk or to target antimicrobial therapy. However, multiple patient
subgroups (for example, immunocompromised, antibiotic-treated) have traditionally been excluded from
randomization. We hypothesized that a prospective surveillance study would better identify patients with suspected
VARI (sVARI) at high risk for adverse clinical outcomes, and who might be specifically targeted in future trials.
Methods: We performed a prospective observational study in all patients ventilated for greater than 48 hours.
sVARI was identified by surveillance for changes in white blood cell count, temperature, sputum, and/or new chest
X-ray infiltrates. Indices of disease co-morbidity, as well as mortality, duration of mechanical ventilation, and length
of hospital or ICU stay were correlated with sVARI.
Results: Of 1806 patients admitted to the ICU over 14 months, 267 were ventilated for greater than 48 hours, and
77 developed sVARI. Incidence of sVARI was associated with iatrogenic immunosuppression or admission for
respiratory illness. Any sVARI, whether suspected ventilator-associated pneumonia (sVAP) or ventilator-associated
tracheobronchitis (sVAT), was associated with increased length of stay and duration of mechanical ventilation.
Conclusions: Clinical surveillance for sVARI identifies patients at risk for increased morbidity. Iatrogenically
immunosuppressed patients, a subgroup previously excluded from randomized clinical trials, represent a growing
proportion of the critically-ill at risk for sVARI who might be targeted for future investigations on diagnostic or
therapeutic modalities.Introduction
Ventilator-associated respiratory infection (VARI), which
includes ventilator-associated pneumonia (VAP) and
ventilator-associated tracheobronchitis (VAT), is a com-
mon acquired infection in the ICU that contributes to
excess length of stay, duration of ventilation, cost and
likely mortality [1,2]. The pathogenesis is thought to
involve predisposition to microbial colonization and
aspiration of pathogenic organisms from the upper
respiratory tract [2]. In agreement, prevention strategies* Correspondence: arnold.kristof@mcgill.ca
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reproduction in any medium, provided the orthat minimize colonization and aspiration (for example,
anti-microbial-coated endotracheal tubes, semi-erect
feeding) have significantly reduced the incidence of VAP
[1]. However, the associated morbidity, antibiotic usage
and cost remain high [3]. Many have advocated the use
of invasive lower respiratory tract sampling to target
pathogenic organisms better and to limit the inappropri-
ate use of antibiotics. Nonetheless, in part due to the
poor predictive value of microbial cultures, current
guidelines reflect ambivalence regarding the utility of
lower respiratory tract sampling and/or quantitative cul-
tures in the management of VAP [1,4].
The use of invasive strategies to improve diagnostic
accuracy and prescribe targeted therapies was examined
in two large trials. In one study, quantitative cultures of
lower respiratory tract samples resulted in reducedLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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recent trial, there was no survival benefit for the use of
invasive techniques [6]. A systematic review based on
these, and two other small clinical trials [7-10], sug-
gested that there is no effect of invasive sampling or
quantitative cultures on mortality in patients with sus-
pected VAP. However, the trials excluded the majority of
screened patients, or those patients with risk factors
commonly encountered in contemporary quaternary
care ICUs (for example, iatrogenic immunosuppression,
previous bacterial colonization, concurrent use of broad
spectrum antibiotics).
Since exclusion of patients at high risk may lead to
underestimation of the effects of interventions on clin-
ical outcomes, we questioned whether the study popula-
tions reflect those patients encountered in current
quaternary care clinical practice. We hypothesized that a
prospective analysis of patients at risk for VARI might
better identify associated risk factors independent of
respiratory tract samples for bacterial diagnosis, and that
VAP need not be distinguished from VAT. Here, we
identify patient subgroups at higher risk of morbidity
that can be targeted, and not excluded, in future clinical
trials on diagnostic and therapeutic modalities in the




Over a period of 14 months (1 May 2007 to 31 July
2008), all patients in the ICU unit at the McGill Univer-
sity Hospital Centre who were mechanically ventilated
for longer than 48 hours were prospectively identified
on a daily basis. All study patients were more than
18 years old. The study was reviewed and approved by
the McGill University Health Centre research ethics
board. Data were collected by prospective or retrospect-
ive chart review or database search, with permission
from the hospital Director of Professional Services, and
as dictated by the approved ethics protocol. Patient
consent was not required for the use of anonymous
chart-based clinical or laboratory data.
Data collection
Prospective data collection for the identification of sus-
pected VARI (sVARI) included the highest temperature
in the last 24 hours, white blood cell count (WBC) and
neutrophil count, as well as increased quantity of re-
spiratory secretions. Sputum was characterized as being
of small, moderate, or large amounts. For patients with
suspected VARI, chest X-ray or computed tomography
(CT) chest changes compatible with pneumonia at the
time of surveillance were identified by two physicians
and a radiologist by inspection of digital images orreports. In addition, at the time of surveillance, we re-
corded the duration of mechanical ventilation in days
and antibiotic or immunosuppressive medications. After
prospective data collection had terminated, we extracted
the following parameters for each patient from our hos-
pital clinical database: age, sex, primary diagnosis at ad-
mission, associated co-morbidities (see Table 1), Acute
Physiology and Chronic Health Evaluation II (Apache II)
score [11], mortality, total duration of mechanical venti-
lation, length of stay in ICU, and length of stay in
hospital. When available, we retrieved results of upper
respiratory tract bacterial cultures for patients with
sVARI.
Definitions
For each patient, sVARI was defined as the first occur-
rence of suspected VAP (sVAP) or suspected VAT
(sVAT). sVAP was defined as a change in the chest X-ray
consistent with pneumonia, and two of the following:
WBC ≥11 or <4, temperature ≥38.0 or <36.0°C, or an in-
crease in sputum. sVAT was defined as an increase in
sputum with WBC ≥11 or <4, and temperature ≥38.0
or <36.0°C (adapted from [12]). Iatrogenically immuno-
suppressed patients were identified prospectively as
those who were administered immunosuppressive
medications (for example, calcineurin inhibitors, anti-
metabolite DNA synthesis inhibitors, lymphotoxic
agents, mTOR inhibitors, high-dose steroids) on the
day of surveillance for sVARI. Other conditions associ-
ated with relative immunosuppression (for example,
diabetes, cancer, liver disease, chronic renal failure)
were accounted for in multivariable analyses. We did
not adjust for rare cases of chemotherapy-induced
neutropenia, as neutropenia was a criterion for the
diagnosis of sVARI.
Statistical analysis
We analyzed all baseline characteristics for the total co-
hort and for groups of patients without or with sVARI.
We explored all variables with frequency distributions
and cross tabulations. For normally distributed continu-
ous data, results were expressed as means ± standard de-
viation and compared using two-tailed Student’s t-test.
For skewed continuous data, results were expressed as
medians ± interquartile range (IQR) and compared using
the Wilcoxon rank sum test. Categorical variables were
compared using a Chi-squared test.
A multivariable analysis was conducted using logistic
regression to assess the association between immuno-
suppression and sVARI. In order to adjust for confound-
ing, a priori chosen covariates were included in the
model. No statistical selection process was used for
model covariate selection. Specifically, we adjusted for
age, diabetes, liver disease, malignancy and chronic renal
Table 1 Baseline clinical characteristics of the total cohort and those with suspected ventilator associated respiratory
infection (sVARI)
Total cohort (267) No VARI (190) Suspected VARI (77) P value
Median age (IQR) 55 (46 to 65) 55(46 to 67) 55(46 to 66) 0.77
Male sex (%) 166 (62.7) 116(61.1) 50(64.9) 0.55
Primary diagnosis
at admissiona
Respiratory 51 (18.8) 30(15.8) 20(26.0) 0.05
Cardiovascular 8 (3.0) 6(3.2) 2(2.6) 0.81
Gastroenterological 20 (7.4) 14(7.4) 6(7.8) 0.91
Neurological 3 (1.11) 3(1.6) 0 0.27
Sepsis 45 (16.6) 29(15.3) 16(20.8) 0.28
Post-operative 109 (40.2) 79(41.6) 28(36.4) 0.43
Post arrest 8 (3.0) 8(4.2) 0 0.07
Other 8 (3.0) 14 (7.4) 5(6.5) 0.80
Co-morbidities
Diabetes 92 (34.0) 64(33.7) 26(33.8) 0.99
COPD/Asthma 51 (18.8) 34(17.9) 17(22.1) 0.43
CAD 132 (48.7) 94(49.5) 36(46.8) 0.69
CHF 77 (28.4) 52(27.4) 25(32.5) 0.41
Liver disease 54 (19.9) 38(20.0) 15(19.5) 0.92
Malignancy 73 (26.9) 47(24.7) 25(32.5) 0.20
Dementia 9 (3.3) 5(2.6) 4(5.2) 0.3
Immunosuppressed 34 (12.7) 17 (9.0) 17(22.1) 0.004
Stroke 29 (10.7) 23(12.1) 6(7.8) 0.31
CRF 75 (27.7) 52(27.4) 23(29.9) 0.68
APACHE II Scoreb (IQR) 27 (22 to 34) 27(21 to 36) 27(22 to 33) 0.83
aNineteen patients had missing initial diagnoses; bAPACHE scores available for 64% of the cohort. The remainder of patients consisted of cardiac surgery
admissions for which the APACHE score has not been validated. APACHE II, Acute Physiology and Chronic Health Evaluation II; COPD, chronic obstructive
pulmonary disease; CAD, coronary artery disease; CHF, congestive heart failure; CRF, chronic renal failure; IQR, interquartile range.
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inclusion of a large proportion of cardiac surgery pa-
tients, for which the APACHE II score was not originally
validated. Multiple linear regression was used to assess
the association between skewed continuous variables (for
example, ICU length of stay, hospital length of stay) and
sVARI while adjusting for a priori covariates. To account
for the skewed nature of the data the continuous out-
come variable was log transformed prior to model deve-
lopment. Statistical analyses were performed using Stata
Version 10.1 (StataCorp LP, College Station TX, USA).
Results
Over the course of 14 months, 1,806 patients were ad-
mitted to the ICU, and in 287 (14.8%) of these the
duration of mechanical ventilation was more than
48 hours. There was a total of 3,202 ventilator days or
2,068 ventilator days per 1,000 patients per year. The
median duration of mechanical ventilation was 10 days
(IQR, 5 to 15 days). During the study period, 77 patientsdeveloped sVARI (Figure 1). Of the 77 patients with
sVARI, 62% had sVAT and 38% sVAP. For the 62 respira-
tory tract microbial cultures retrospectively retrieved in
patients with sVARI, the spectrum of organisms was
similar to that observed in other quaternary care ICUs
(see Additional file 1). The median time to sVARI was
five days (IQR, three to eight days), and one third
occurred within three days of initiation of mechanical
ventilation (see Additional file 2).
We determined baseline demographics, as well as indica-
tors of diagnostic spectrum or severity of illness (Table 1).
The median age was 55 years, and two thirds of the patients
were men. The most common reason for admission was
for post-operative monitoring after complicated surgery or
intra-operative complications. Respiratory illness or sepsis
were also common diagnoses, and together accounted for
one third of admissions to the ICU. The most frequent
comorbidities were diabetes and coronary artery disease.
Active malignancy and iatrogenic immunosuppression
(referred to as immunosuppression from here on) were
Figure 1 Patient flow. A flow diagram for patients at risk for
suspected ventilator-associated pneumonia, and identification of
patients with suspected ventilator-associated tracheobronchitis (sVAT)
or suspected ventilator-associated pneumonia (sVAP), are shown.
Table 2 Clinical outcomes of total cohort and patients























39 (19 to 80) 34(16 to 69) 60(33 to 129) <0.001
aP value relates to patients with and without suspected VARI; b21 patients
(11%) with missing data for vent days. IQR, interquartile range; VARI,
ventilator-associated respiratory infection.
Table 3 Association between immunosuppression and








Immunosuppressed 3.34 1.47 to 7.61 0.004
Age
<50 1.0 -
50 to 70 0.78 0.34 to 1.79 0.36
>70 0.89 0.38 to 2.11
Diabetes 0.94 0.51 to 1.73 0.87
Liver disease 0.78 0.37 to 1.61 0.50
Malignancy 1.30 0.71 to 2.39 0.85
CRF 0.92 0.51 to 1.73 0.80
CRF, chronic renal failure; sVARI, suspected ventilator-associated respiratory infection.
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tients, respectively. The median APACHE II score was
27 (IQR, 22 to 34).
In immunosuppressed patients, sVARI occurred more
commonly than no sVARI (22.1% versus 9%, P = 0.004).
Other than patients admitted with respiratory disease
(sVARI 26% versus no sVARI 15.8%, P = 0.05), there were
no significant differences for other co-morbidities listed in
Table 1. Of the 77 patients with a new diagnosis of sVARI,
51 (66%) were concurrently undergoing administration of
broad spectrum antibiotics. Patients with sVARI had in-
creased duration of mechanical ventilation, ICU and hos-
pital length of stay, but not mortality, when compared to
patients with no infection (Table 2). When compared to
non-immunocompromised patients with sVARI, those who
were immunocompromised exhibited increased median
ICU length of stay (26 days, IQR 20 to 44 versus 16 days,
IQR 11 to 31; P = 0.08) and hospital length of stay (113 days,
IQR 76 to 154 versus 46 days, 95% CI 29 to 91; P <0.002),
but not mortality (47% versus 35%; not significant) or du-
ration of mechanical ventilation (9 days, IQR 4 to 15 versus9 days, IQR 6 to 15; not significant). In a multivariable ana-
lysis, immunosuppression was significantly associated with
sVARI even after adjusting for other chronic diseases
associated with reduced immune function (odds ratio 3.34,
95% CI 1.47 to 7.61, P = 0.004) (Table 3).
We next determined the distribution of sVARI sub-
types, and their effects on patient outcomes. Forty-eight
(62%) patients with sVARI had tracheobronchitis (sVAT)
(see Additional file 1). Of the 29 (38%) patients with sVAP,
19 exhibited abnormal white blood cell count or sputum
production, but not temperature. Only three patients with
sVARI developed all four diagnostic criteria for sVAP.
These data indicate that the classical signs and symptoms
associated with VAP are often absent, and that sVAT
occurs in a large proportion (62%) of patients with sVARI.
We therefore determined whether sVAP and sVAT dif-
fered in their effects on ICU or hospital length of stay.
When compared with patients with no infection, those
with sVAP had a significantly increased ICU (16 days,
IQR 12 to 24 versus 11 days, IQR 7 to 20, P <0.01) or
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to 69, P <0.01) length of stay (Figure 2). Patients with
sVAT had increased ICU (19 days, IQR 11 to 44 versus
11 days, IQR 7 to 20, P <0.003) or hospital (64 days,
IQR 32 to 152 versus 34 days, IQR 16 to 69, P <0.001)
length of stay. In a separate multivariable analysis, after
adjusting for immunosuppressive medications, age, dia-
betes, liver disease, cancer and chronic renal failure,
there was a 1.8-, 2.0-, and 1.5-fold increase in ICU
length of stay for patients with sVARI, sVAT, and sVAP,
respectively (each P <0.001). Similarly, there was a 1.6-,
1.8-, and 1.6-fold increase in hospital length of stay for
patients with sVARI, sVAT and sVAP, respectively
(P <0.001). These data indicate a significant effect of
sVAP and sVAT on length of stay even when adjusting
for immunosuppression.Figure 2 ICU or hospital length of stay in patients with sVAP or sVAT
values ± interquartile range (IQR) are shown for A) ICU length of stay (days
no infection by Wilcoxon rank sum test. sVAP, suspected ventilator-associatDiscussion
In this study, we assessed the incidence, risk factors and
clinical outcomes of sVARI over a 14 month period in
the 267 patients who were ventilated for more than
48 hours in a quaternary care ICU. The diagnosis of
sVARI incorporated ventilator-associated complications
independent of bacteriological diagnosis and was associ-
ated with iatrogenic immunosuppression (that is, pa-
tients on immunosuppressive agents at the time of
surveillance for sVARI) and respiratory illness, as well as
an increased duration of mechanical ventilation, or
length of stay in the ICU or hospital. Whereas most stu-
dies have focused on VAP, we found that sVAT was also
associated with increased ICU or hospital length of stay.
The rate of sVAT (18%) was slightly higher than that pre-
viously reported for VAT (that is, that incorporating. For patients with no suspected infection, sVAT or sVAP, median
) or B) hospital length of stay (days). P <0.003 for sVAT or sVAP versus
ed pneumonia; sVAT, suspected ventilator-associated tracheobronchitis.
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ported a frequency of 11.5% [14]. In support of the clinical
importance of VAT, VAT and VAP had similar impacts on
outcomes in a study where bacterial cultures were taken
into account [13]. Moreover, anti-bacterial treatment of
VAT increased mechanical ventilation-free days and sur-
vival in a small randomized trial [15]. Although our results
suggest that clinical indicators of ventilator-associated
respiratory tract infection identify patients at risk for
adverse outcomes, the effect of respiratory tract sam-
pling on patient outcomes or anti-bacterial usage in
high-risk patients (for example, immunocompromised),
or those already undergoing antibiotic therapy, remains
unknown.
We report that iatrogenically immunosuppressed pa-
tients are at increased risk for VARI, which in turn
impacts upon ICU and hospital length of stay. In agree-
ment, patients with sVARI who were immunocomprom-
ised exhibited an increased duration of ICU and hospital
stay when compared to those who were not immuno-
compromised. Consistent with our observations, a large
surveillance study revealed that immunosuppression is
an independent predictor of all infections in the ICU
and more than 50% of infections were respiratory [16].
This subgroup of patients has been traditionally ex-
cluded from randomized trials on VAP. Moreover, in re-
cent years, the use of immunosuppressive agents for
transplantation or chronic inflammatory disease has
dramatically increased, and this group of patients now
represents a significant proportion of quaternary ICU
admissions. Unlike randomized trials with heteroge-
neous patient populations [6], targeting a limited popu-
lation at increased risk might shed light on the specific
effects of lower respiratory tract sampling and microbial
ecology on clinical outcomes in future studies.
Our prospective trial design permitted the assessment
of sVARI on clinical outcomes independent of biases
introduced by retrospective chart review. The large
number of patients with solid organ and bone marrow
transplantation in our ICU permitted the evaluation of
factors associated with immunosuppression, which may
have been missed by previous surveillance studies [12].
In fact, patients with active malignancy or immunosup-
pression represented 40% of our cohort. Reassuringly,
demographics (for example, age, co-morbidities, admis-
sion diagnosis; Table 1) and microbial ecology (see
Additional file 1) were comparable to previous studies
on ventilator-associated infections, with the exception of
patients with trauma, burn and primary neurological
presentations. Consistent with previous studies, a pri-
mary respiratory diagnosis on admission was associated
with sVARI [2]. Median duration of mechanical ventila-
tion, APACHE II scores, rates of ventilator-associated
complications, mortality and length of ICU or hospitalstay (Tables 1 and 2) were also similar to those in other
reports on patients who were ventilated for >48 hours
[17]. Moreover, as previously reported [13], the majority
of ventilator-associated events occurred within six days of
initiation of mechanical ventilation (see Additional file 2).
We detected a significant association between im-
munosuppression and sVARI (Table 3, odds ratio 3.3,
IQR 1.5 to 7.6). In addition, patients with sVARI exhib-
ited increased ICU and hospital length of stay if they
were immunosuppressed. However, due to a relatively
low event rate (77 patients with sVARI), one limitation
of our study was suboptimal power to rule out differ-
ences between certain groups, or to use our dataset to
discover new markers of sVARI or related adverse clin-
ical outcomes. Moreover, although the spectrum of or-
ganisms was similar to that observed in other studies on
VAP (see Additional file 1), we did not collect microbio-
logical samples for all patients and time points; we
could, therefore, not assess the relationship between type
of bacterial infection and demographic characteristics or
clinical outcomes. With regard to the latter, many would
argue that poor standardization and specificity renders
bacteriological diagnosis suboptimal for the diagnosis of
VAP or VAT, although they may be useful for surveil-
lance (http://www.cdc.gov/nhsn/acute-care-hospital/vae).
This may, in part, be due to the common use of broad
spectrum antibiotics at the time of surveillance. In the
current study, 66% of the patients were on broad-
spectrum antibiotics at the time of sVARI. Similar anti-
biotic usage rates have been demonstrated in previous
studies [13,15,16]. Importantly, patients on prior antibi-
otics were excluded from a negative trial evaluating
lower respiratory tract sampling in VAP [6].
Conclusions
In summary, mechanically-ventilated patients at risk for
adverse clinical outcomes can be identified on clinical
grounds. Patients at risk include those who develop sus-
pected VAP or VAT (that is, sVARI) and those who are
iatrogenically immunosuppressed. Observational studies
with larger sample sizes can be performed to rule out
other risk factors for sVARI that were not identified in
our study as statistically significant. Iatrogenically im-
munosuppressed patients represent an emerging popula-
tion at risk for VARI that can be targeted in future
randomized trials on the role of diagnostic or thera-
peutic modalities in ventilator-associated complications.
Although there is a current emphasis on the identification
of ‘ventilator-associated events (VAEs)’ as quality indicators
in hospital-based health care delivery (http://www.cdc.gov/
nhsn/acute-care-hospital/vae), our data highlight the im-
portance of suspected VARIs as an important outcome for
the development of targeted diagnostic and therapeutic
strategies.
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 Suspicion of ventilator-associated respiratory infec-
tion based on clinical criteria is associated with
iatrogenic immunosuppression in critically ill patients.
 Suspicion of ventilator-associated pneumonia or
tracheobronchitis is equally associated with adverse
clinical outcomes.
 We identified patient groups at high risk for adverse
outcomes that can be targeted in future clinical
trials on diagnostic and therapeutic modalities for
ventilator-associated infections.
 Despite the current enthusiasm for a focus on
ventilator-associated events as an outcome for
hospital-acquired infections, VARIs remain impor-
tant for identifying patients who might derive benefit
from targeted diagnostic or therapeutic modalities.
Additional files
Additional file 1: Table S1. Organisms isolated in patients with
suspected ventilator-associated respiratory infection; Table S2: Breakdown
of diagnostic criteria for patients with sVARI.
Additional file 2: Frequency distribution of sVARI by days of
mechanical ventilation. Data shown are a frequency distribution
representing the number of incident sVARIs by duration of mechanical
ventilation.
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